title: CCR3: Shedding new light on a dark problem?
abstract: A recent work by Ambati et al. represents a bold step towards a more effective diagnosis and treatment of age-related macular degeneration, with the new evidence showing that CCR3, a chemokine receptor, is an early marker of and potential therapeutic target for choroidal neovascularization development. In the wake of such a novel and significant finding, additional illumination to confirm and consolidate the promise shown by CCR3 will soon follow.
authors.affiliation: Yale University School of Medicine, New Haven, CT 06510, USA. alan.mason@yale.edu
authors.forename: A Brett
authors.initials: AB
authors.lastname: Mason
authors.forename: Josephine
authors.initials: J
authors.lastname: Hoh
mesh_terms: D000818:Animals; D020256:Choroidal Neovascularization / Q000150:complications / Q000628:therapy; D004195:Disease Models, Animal; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000628:therapy; D051379:Mice; D054397:Receptors, CCR3 / Q000276:immunology / Q000378:metabolism*; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D054397:Receptors, CCR3; D042461:Vascular Endothelial Growth Factor A